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Abstract
Background
Poor sleep quality (SQ) is common after solid organ transplantation; however, very little is
known about its natural history. We assessed the changes in SQ from pre- to 3 years post-
transplant in adult heart, kidney, liver and lung recipients included in the prospective nation-
wide Swiss Transplant Cohort Study. We explored associations with selected variables in
patients suffering persistent poor SQ compared to those with good or variable SQ.
Methods
Adult single organ transplant recipients enrolled in the Swiss Transplant Cohort Study with
pre-transplant and at least 3 post-transplant SQ assessment data were included. SQ was
self-reported pre-transplant (at listing), then at 6, 12, 24 and 36 months post-transplant. A
single SQ item was used to identify poor (0–5) and good sleepers (6–10). Between organ
groups, SQ was compared via logistic regression analysis with generalized estimating equa-
tions. Within the group reporting persistently poor SQ, we used logistic regression or
Kaplan-Meier analysis as appropriate to check for differences in global quality of life and
survival.
Results
In a sample of 1173 transplant patients (age: 52.1±13.2 years; 65% males; 66% kidney,
17% liver, 10% lung, 7% heart) transplanted between 2008 and 2012, pre- transplant poor
SQ was highest in liver (50%) and heart (49%) recipients. Overall, poor SQ decreased sig-
nificantly from pre-transplant (38%) to 24 months post-transplant (26%) and remained
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stable at 3 years (29%). Patients reporting persistently poor SQ had significantly more
depressive symptomatology and lower global quality of life.
Conclusion
Because self-reported poor SQ is related to poorer global quality of life, these results
emphasize the need for further studies to find suitable treatment options for poor SQ in
transplant recipients.
Background
After a successful transplantation, loss of sleep quality (SQ) typically reduces’ recipients’ qual-
ity of life and may impair survival. However, during follow-up, sleep quality (SQ) self-reports
have rarely been collected via standardized protocols. To be feasible, the measurement has
to be simple, valid and reliable. Therefore, to differentiate poor from good sleepers, we used a
single item from the sleep subscale of the Kidney Disease and Quality of Life–Short Form
(KDQoL-SF): “On a scale from 0–10, how would you evaluate your sleep?” Scores of 0–5 were
classed as poor; 6–10 indicated good SQ. This item is not yet part of a standardized protocol,
and sleep quality is not yet a standardized follow-up criterion.
Poor sleep quality (SQ) is common in hemodialysis patients (49%-53% prevalence) [1, 2].
Kidney transplantation is expected to correct most kidney disease-related abnormalities of the
kidney disease and significantly improve the patients’ health. However, a 2011 study reported
high (31%) prevalence of poor SQ after kidney transplantation [3]. This may reflect a serious
risk regarding patient survival. The Dialysis Outcomes and Practice Patterns Study collected
SQ data from 11351 patients in 308 dialysis units across seven countries and reported a 16%
higher relative risk of mortality in hemodialysis patients with poor SQ compared to good
sleepers [1]. Such a strong link with overall wellbeing and health indicates an equally strong
need to detect and understand poor SQ as a post-transplantation health outcome. Patient-
reported outcomes (PROs) including SQ are becoming extremely important indicators of the
quality of patient care [4]. To date, however, no studies have used PROs (e.g., sleep quality)
simultaneously in kidney, heart, liver and lung transplant patients to monitor global quality of
life and survival. Data on SQ in kidney, heart, liver and lung transplant patients are scarce, and
longitudinal studies are even more so. Therefore, based on data from the Swiss Transplant
Cohort Study, the current analysis had three aims: (1) to detect and compare changes in SQ in
kidney, heart, liver and lung transplant recipients over time (pre-, 6, 12, 24, and 36 months
post-transplant); (2) to compare solid organ transplant recipients groups (kidney, heart, liver
and lung) with persistent poor SQ over time; and (3) to compare global quality of life and sur-
vival over time (until 3 years post-transplant) in subjects with persistently poor SQ as opposed
to those with consistently good and variable SQ.
Materials and methods
Design, sample and setting
For this study we used data from the Swiss Transplant Cohort Study, a prospective open cohort
study including 1173 patients transplanted in one of the six Swiss transplant centers (Lau-
sanne, Geneva, Basel, Zu¨rich, Bern, St. Gallen). Details of that study are published elsewhere
[5]. Kidney, heart, liver and lung transplant recipients were eligible if they were aged 18 years
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or older, has received a single transplant (i.e., no multiple-organ transplants) enrolled from
May 2, 2008 until February 2, 2012, and were followed up until August 11th, 2015. After pro-
viding written informed consent, organ transplant candidates completed the psychosocial
questionnaire (socio-demographic, psychosocial, and behavioral variables, including SQ), pre-
transplant (at the time of listing), 6 months post-transplant, 1 year post-transplant, and each
year thereafter (described elsewhere) [5, 6]. The Swiss Transplant Cohort Study was approved
by the ethics committees overseeing the 6 participating transplant centers. None of the trans-
plant recipients received organs from vulnerable populations, as all organ transplantation is
regulated by Swiss law. All donors or next of kin freely provided written informed consent.
Variables and measurements
Sleep quality. Sleep quality (SQ) was assessed with a single item derived from the ‘Kidney
Disease Quality of Life–Short Form’ instrument, which was initially developed for patients
with end-stage renal disease [1]. Patients were asked, “On a scale of 0 to 10 [where 0 represents
‘very bad’ and 10 represents ‘very good’], how would you rate your sleep quality overall?”
Based on ROC curve analysis, values below 6 indicated poor SQ [3]. Therefore, we used<6 as
a cut-off to define poor SQ [3]. Content validity was good (content validity index (CVI): .81).
Concurrent validity (i.e., in relation to the Pittsburgh Sleep Quality Index (rs: -.737 p< .01))
and discriminant validity (i.e., versus depression diagnosis and the Depression, Anxiety and
Stress scale, and quality of life as measured with the EQ-5D) were good [3]. Predictive validity
of the SQ item was demonstrated in the Dialysis Outcome and Practice Pattern Study, [1] as
poor SQ predicted mortality.
For our second and third aims, we divided patients into two groups based on the longitudi-
nal pattern of their SQ: those who had persistent poor SQ versus all others (transplant recipients
with consistently good or variable sleep quality). As at least two post-transplant measurement
points were needed to define patients with persistent poor SQ, inclusion was limited to patients
who survived at least 1 year post-transplant.
Socio-demographic and clinical variables. Six socio-demographic variables were extracted
from the Swiss Transplant Cohort Study database [5, 6]: gender, age in years at the time of trans-
plantation, transplanted organ (kidney, liver, heart, or lung), time between study inclusion and
transplantation, highest completed educational level (never completed high school, high school
graduate, some college, college graduate) and marital status (single, married/living together,
widow/widower, divorced, separated). We also extracted two clinical variables: main immuno-
suppressive regimen (Azathioprine, Tacrolimus, Cyclosporine, Rapamune, Mycophenolate Acid)
and the two most frequent etiologies of the disease pre-transplant (heart transplant: dilated car-
diomyopathy and ischemic heart disease; kidney transplant: glomerulonephritis and polycystic
kidney disease; liver transplant: hepatitis C and alcohol; lung transplant: chronic obstructive pul-
monary disease and cystic fibrosis).
Depressive symptomatology was assessed via the 7-item depression subscale of the Hospital
Anxiety and Depression Scale, a self-reported non-diagnostic screening instrument. This scale
is widely used and well-validated as a screening instrument for depression in the general medi-
cal population, and, to some extent, in kidney transplantation contexts [7]. The mean scores
for depression in a general German population (N = 4410) were 4.8 (males) and 4.7 (females)
[8]. Each item is scored on a scale from 0 to 3, with the total score calculated by summing the
seven individual item scores (range: 0–21). A cut-off of8 was used to indicate depression [9].
Sensitivity of the HADS depression subscale using this cut-off was 0.86; specificity was 0.81 for
depressive disorder screening [10].
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Global quality of life was assessed with a visual analogue scale from 0 (worst imaginable
quality of life to 100 (best imaginable quality of life). This scale is both widely used and vali-
dated for use in German-language settings [6, 11] where it has shown high levels of validity
and reliability [12]. The mean score for global quality of life in the general German population
was 77.1±17.8 [13]. We used this variable as an outcome as it measures a broad construct of
health (a summary of numerous health issues facing transplant recipients) that is close to the
transplant recipient’s perspective [12]. Survival was defined as the estimated fraction of trans-
plant recipients who would survive over the six years of the study period, it was used as a func-
tion to estimate the probability that transplant recipients with poor SQ would eventually differ
from those with consistently good or variable SQ after transplantation.
Statistical analysis
Descriptive analyses of sample characteristics were performed using frequencies, proportions,
measures of central tendency (means, medians) and dispersion (standard deviations, inter-
quartile ranges) as appropriate for measurement levels and distributions. Differences in demo-
graphic and clinical characteristics among organ groups were screened using Chi-square or
Wilcoxon rank-sum tests.
Changes in poor SQ over time for the various organ recipient groups and the overall sample
were depicted graphically. They were also modeled via logistic regression analyses using gener-
alized estimating equations to account for the repeated measures [14], and controlling for
organ group, age, gender, depressive symptomatology, co-morbidities, immunosuppressive
regimen and the time that elapsed between baseline measurement (the pre-transplant psycho-
social questionnaire) and transplantation. The model presented was adjusted by retaining only
significant covariates.
Two sub-analyses were also performed. The first used an interaction between organ group
and time category to generate odds ratio comparisons based entirely on pre-transplant data.
The second, performed using post-transplant data, incorporated time as a continuous variable
to allow the estimation of linear trends over the post-transplant period. To examine the possi-
ble effect of missing follow-up data on model stability, analyses were also performed using a
Last-Observation-Carried-Forward (LOCF) imputation strategy.
For our second and third aims, we divided patients into two groups based on their longitu-
dinal sleeping patterns: those who had persistent poor SQ and all others. As at least two post-
transplant measurement points were needed to define patients with persistent poor SQ, inclu-
sion was limited to patients who survived at least 1 year post-transplant.
Differences between patients with persistently poor SQ versus those with consistently good
or variable SQ were explored via descriptive analyses, and using Chi-square, Wilcoxon rank-
sum tests, or Kaplan-Meier estimates as appropriate. We determined both global quality of life
and survival via Kaplan Meier analyses, and compared the results with those with consistently
good or variable SQ. All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC,
USA) software. The alpha level was set at 5%.
Results
Sample characteristics overall
As of February 2, 2012, the Swiss transplant cohort study included 1597 patients, of whom
1173 fulfilled the current study’s inclusion criteria: 770 (65%) kidney, 201 (18%) liver, 123
(10%) lung and 79 (7%) heart transplant candidates. Fig 1 depicts the overall sample size and
the number of included respondents per organ group at each data collection point. Demo-
graphics and clinical characteristics of the 1173 transplant recipients included in the analyses
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are provided in Table 1. At pre-transplant measurement, the average patient age was 50.1±13.2
years; almost two-thirds (65.5%) were male; and most (66.1%) were married or living with a
partner. The median period between pre-transplant assessment and transplantation was 7.7
±9.6 months.
The follow-up time ranged from 18 months to 7.1 years, with a median of 4.1 years (inter-
quartile range 2.0). Of the 1173 patients included in the study at the pre-transplant measure-
ment, 894 (76.2%) had available data over 36 months. One hundred, eight (9.2%) patients had
died by the end of the study.
Of the 765 kidney insufficient patients, 16% (N = 119) were transplanted pre-emptively
(estimated GFR (eGFR) was 10 ml/min/1.73m2), 69% (N = 531) were on hemodialysis and
15% (N = 115) on peritoneal dialysis. The mean time on dialysis was 4.0±5.0 years. The eGFR
at 36 months was 55 ml/min/1.73m2 post-kidney transplantation and 72 ml/min/1.73m2 post-
liver transplantation. The pre-liver-transplantation MELD score was 20±9 and the pre-heart-
transplantation Ejection Fraction was 24.4±13.0%.
Fig 1. Flow diagram showing the sample as selected from the swiss transplant cohort study overall sample.
https://doi.org/10.1371/journal.pone.0185036.g001
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Table 1. Sample characteristics at pre-transplant for all organs and per organ group.
Pre-Tx All Heart Kidney Liver Lung P-value
Assessed at listing N = 1173
(100%)
N = 79
(6.73%)
N = 770
(65.64%)
N = 201
(17.14%)
N = 123
(10.49%)
Age Mean (std) in years (Age range 18–79
years)
52.06 ±13.21 50.66
±12.2
52.13
±13.74
53.65 ±10.86 49.91
±13.68
0.16
Gender Male–N (%) 768 (65.47) 64 (81.01) 513
(66.62)
132 (65.67) 59 (47.97) <
.0001
Living situation Divorced–N (%) 110 (9.47) 10 (12.82) 61 (8.02) 23 (11.56) 16 (13.01) 0.098
Married/living together–N (%) 768 (66.15) 45 (57.69) 510
(67.02)
138 (69.35) 75 (60.98)
Separated–N (%) 35 (3.01) 5 (6.41) 18 (2.37) 7 (3.52) 5 (4.07)
Single–N (%) 219 (18.86) 15 (19.23) 148
(19.45)
30 (15.08) 26 (21.14)
Widow/widower–N (%) 29 (2.5) 3 (3.85) 24 (3.15) 1 (0.5) 1 (0.81)
Missing = 12
Highest completed
educational degree
Never completed high school N (%) 807 (69.15) 55 (69.62) 531
(69.41)
135 (67.5) 86 (69.92) 0.961
High school graduate N (%) 73 (6.25) 7 (8.86) 45 (5.88) 15 (7.5) 6 (4.88)
Some college N (%) 177 (15.17) 12 (15.19) 114 (14.9) 31 (15.5) 20 (16.26)
College graduate N (%) 110 (9.42) 5 (6.33) 75 (9.8) 19 (9.5) 11 (8.94)
Missing = 6
Depressive Median (25th; 75th Percentile) 4 (2; 7) 5 (3; 8.17) 4 (2; 6) 4 (2; 7) 5 (3; 8) < .0001
symptomatology Missing = 20
Global quality of life Mean (std) range 0–100 Missings = 55 55.82±22.50 43.47
±17.53
59.98
±21.70
55.26 ±23.69 38.77
±16.70
< .0001
Time between inclusion in
STCS and Tx
Mean (std) in years -7.96 ±9.58 -5.96 ±6.7 -8.92
±10.76
-4.92 ±5.64 -8.26
±6.83
0.0002
Pre-Tx All Heart Kidney Liver Lung P-value
Assessed at Tx Time
Comorbidities History of cancer–N (%) 224 (19.1) 11 (13.92) 111
(14.42)
83 (41.29) 19 (15.45) < .0001
Missing = 0
History of Cardiopulmonary diseases–N
(%)
662 (56.44) 79 (100) 393
(51.24)
67 (33.33) 123 (100) 0.043
Missing = 3
History of metabolic, endocrine or kidney
diseases–N (%)
1054 (89.85) 66 (83.54) 770 (100) 142 (70.65) 76 (61.79) < .0001
Missing = 0
History of skin cancer–N (%) 62 (5.28) 3 (3.8) 45 (5.85) 6 (2.99) 8 (6.5) 0.93
Missing = 1
Nr. Comorbidities at time of
Tx
Median (25th; 75th Percentile) 2 (1; 2) 2 (2; 2) 2 (1; 2) 1 (1; 2) 2 (1; 2) <0.0001
Missing = 0
IS at time of Tx Azathioprine-Tacrolimus 32 (2.74) 20 (25.32) 8 (1.04) 3 (1.52) 1 (0.81)
(Percentage based on Cyclosporine- Mycophenolate A 270 (23.16) 43 (54.43) 116
(15.14)
36 (18.18) 75 (60.98)
Organ group) Cyclosporine- EC-Mycophenolate A 66 (5.66) 2 (2.53) 61 (7.96) 1 (0.51) 2 (1.63)
Tacrolimus 745 (63.83) 10 (12.66) 555
(72.45)
135 (68.18) 45 (36.59)
Other immunosuppressiva 45 (3.86) 4 (5.06) 20 (2.61) 21 (10.61) 0 (0)
Rapamune—Mycophenolate Acid 8 (0.69) 0 (0) 6 (0.78) 2 (1.01) 0 (0)
(Continued )
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Changes of poor sleep quality between organ groups over time
Fig 2 shows the percentages of patients with poor SQ at each data collection point. Pre-trans-
plant, 38% of the sample reported poor SQ. At 24 months post-transplant, poor SQ was
reported at its lowest level (26%). Fewer heart, kidney and liver transplant recipients reported
poor SQ at six months compared to pre-transplant (Table 2). For the kidney and liver transplant
groups, this improvement continued until the 1-year measurement. Overall, as illustrated in
Table 3, patients’ odds of poor SQ were higher at baseline (OR 1.45; 95%CI: 1.21–1.74) and 6
months post-transplant (OR 1.44; 95%CI: 1.21–1.72) compared to 24 months post-transplant.
Pre-transplant liver patients reported the highest occurrence of poor SQ (50%), followed
closely by heart transplant candidates (49%). Both these groups differed significantly from
their lung transplant (32%) and kidney transplant (34%) counterparts (Table 3). A decrease in
poor SQ among kidney (OR 0.91; 95%CI: 0.84–0.97; p = 0.005; Table 4) and liver transplant
recipients (OR 0.80; 95%CI: 0.69–0.93; p = 0.004) could be observed via linear modeling of
post-transplant developments (Table 4). Other organ recipient groups showed no statistically
significant changes over time. In terms of estimates and inferences, replacing missing values
by imputing the last observed values yearly until the end of the observation period only moder-
ately (not statistically significant) affected the results in any of the tables.
Sample characteristics and correlates for transplant recipients with
persistent poor SQ
Table 5 shows the characteristics of the overall sample at 6 months post-transplant, alongside
those of persistent poor SQ and of all others (those with consistently good or variable SQ). The
persistently poor SQ group accounted for 10% of the sample (N = 107; 10.4%). Poor SQ was
more prevalent in patients with lower education (p = 0.03) and in those with more depressive
symptoms (p =< .0001).
Global quality of life and Survival for Patients with persistent poor SQ
Pre-transplant, the global quality of life rating was 55.9±22.6; 6 months post-transplant, it
increased to 74.3±17.7. Graft recipients with persistently poor SQ over time had a significantly
Table 1. (Continued)
Total 1166 (100) 79 (6.78) 766
(65.69)
198 (16.98) 123
(10.55)
0.381
Missing = 7
IS at 6 Months Azathioprine-Tacrolimus 28 (2.8) 3 (4.41) 19 (2.89) 4 (2.35) 2 (1.9)
(Percentage based on Cyclosporine- Mycophenolate A 189 (18.89) 24 (35.29) 80 (12.16) 28 (16.47) 57 (54.29)
Organ group) Cyclosporine- EC-Mycophenolate A 49 (4.89) 2 (2.94) 39 (5.93) 2 (1.18) 6 (5.71)
Tacrolimus 664 (66.34) 29 (42.65) 492
(74.77)
105 (61.76) 38 (36.19)
Other immunosuppressiva 52 (5.19) 6 (8.82) 16 (2.43) 28 (16.47) 2 (1.9)
Rapamune—Mycophenolate Acid 19 (1.9) 4 (5.88) 12 (1.82) 3 (1.76) 0 (0)
Total 1001 (100) 68 (6.79) 658
(65.73)
170 (16.98) 105
(10.49)
<0.0001
Missing = 6
Legend: Tx = transplantation; std = standard deviation; STCS (Swiss Transplant Cohort Study); AZA = Azathioprine; TAC = Tacrolimus;
CSA = Cyclosporine; Rap = Rapamune; MPA = Mycophenolate Acid; MPA-EC = Enteric-coated Mycophenolate Acid; IS = Immunosuppression;
COPD = Chronic Obstructive Pulmonary Disease
https://doi.org/10.1371/journal.pone.0185036.t001
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lower mean global quality of life (59.7±21.5; p =< .0001) compared to those with consistently
good or variable SQ. This result was consistent when controlling for organ group, age, gender,
comorbidities and time between inclusion in the Swiss Transplant Cohort Study and trans-
plantation. Missing data over time did not change the results (as determined by a sensitivity
analysis using a last observation carried forward imputation method). At 6 years post-trans-
plant, survival probability was 0.83 for those with consistently good or variable SQ and 0.79 for
patients with persistent poor SQ (not significant).
Fig 2. Change in poor SQ from pre-transplant to 3 years post-transplant (overall & per transplant group).
https://doi.org/10.1371/journal.pone.0185036.g002
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Discussion
To the best of our knowledge, the current work represents the largest study to date to simulta-
neously investigate self-reported SQ in heart, lung, liver and kidney transplant groups using a
single protocol. We found that poor SQ affected roughly one-third of transplant recipients
throughout the measurement period, but generally improved from pre-transplant until 1 year
post-transplant. Significant differences in perceived SQ were observed between organ groups.
As reported in previous studies, poor SQ is common pre- and post-transplant; however, those
studies were limited regarding follow-up periods and sample sizes, and used various SQ assess-
ment methods.
Changes in poor sleep quality over time
The range of poor SQ measured with the Pittsburgh Sleep Quality index is extremely wide in
the published studies: 28–69% in heart [15], 8–62% in kidney [3, 15–21] [22], 51–72% in liver
Table 2. Modeling of poor SQ over time and across different organ transplant groups.
Contrast Odds ratio (95% confidence interval) Chi2 value p-value
Intercept 0.12 (0.09;0.17) 164.7 < .0001
Male Gender 1.44 (1.18;1.77) 13.2 0.0003
Depressive symptomatology + 1.23 (1.20;1.25) 297.46 < .0002
Measurement Point Baseline vs 24 months post-Tx (*) 1.45 (1.21;1.74) 16.73 < .0002
6 months post-Tx vs 24 months post-Tx 1.44 (1.21;1.72) 17.21 < .0002
12 months post-Tx vs 24 months post-Tx 1.19 (1.00;1.42) 3.8 0.0512
36 months post-Tx vs 24 months post-Tx 1.13 (0.96;1.33) 2.18 0.14
Kidney vs Liver 0.74 (0.59;0.94) 6.18 0.0129
Lung vs Liver 0.73 (0.50;1.06) 2.81 0.0939
Heart vs Liver 1.04 (0.66;1.63) 0.03 0.874
Lung vs Kidney 0.98 (0.71;1.37) 0.01 0.9135
Kidney vs Heart 0.72 (0.47;1.09) 2.45 0.1176
Heart vs Lung 1.42 (0.85;2.37) 1.83 0.1756
Explanation: Logistic regression model predicting poor SQ (N = 1173). We controlled for organ group, age, gender, depressive symptomatology, co-
morbidities, immunosuppressive regimen and the time that elapsed between baseline measurement and transplantation. Only significant confounders were
retained in the final model.
Legend: SQ: Sleep quality; Tx: transplantation; STCS: Swiss Transplant Cohort Study; + = Variable used as a continuous and time dependent variable
(*) Odds ratio can be interpreted as the adjusted odds of poor SQ at enrolment compared to the reference category of poor SQ at 24 months.
https://doi.org/10.1371/journal.pone.0185036.t002
Table 3. Differences in poor SQ over time between organ transplant groups pre-Tx.
Contrast Odds ratio (95% confidence interval) Chi2 value p-value
Heart vs Kidney 0.27 (-1.13;-0.06) 4.69 0.0303
Liver vs Kidney 0.17 (-0.97;-0.3) 14.15 0.0002
Lung vs Kidney 0.23 (-0.01;0.9) 3.7 0.0543
Heart vs Liver 0.3 (-0.54;0.63) 0.02 0.8818
Heart vs Lung 0.34 (-1.71;-0.37) 9.34 0.0022
Liver vs Lung 0.26 (-1.6;-0.57) 17.01 < .0001
Explanation: Model of Table 2 (controlled for gender and depressive symptomatology), with an added
interaction between organ groups and time categories. Only contrasts between organ groups are reported.
https://doi.org/10.1371/journal.pone.0185036.t003
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[15, 23, 24] and 32–54% in lung transplant recipients [15, 25]. Measured with the Pittsburgh
Sleep Quality Index the prevalence of poor SQ in the general population ranges from 22% [26]
to 45% [27]. As there are no prevalence data of poor SQ assessed with the single SQ item we
cannot conclude that our prevalence is higher than in the general population. The most appro-
priate conclusion drawn from these results is the comparison of the prevalence of poor SQ
across organ transplant groups and over time.
The improvement indicated from pre- to post-kidney transplantation confirms the findings
of previous studies [21]. For example, one recent study showed that 46% of kidney transplant
recipients experienced a clinically relevant improvement in overall sleep quality, while 21%
experienced a clinically relevant deterioration [21] over 5 years of follow up. Over time, kidney
and liver transplant recipients showed a significant decrease in poor SQ. The drop might be
connected with the normalization of life with a transplanted organ and return to work [28].
Compared to heart and lung groups [29], the fear of rejection and the frequency of follow-up
visits are normally reduced at 36 months post-kidney and liver transplantation. Liaveri et.al.’s
study in renal transplant recipients reported improved quality of life after transplantation;
however this benefit does not seem to extend to sleep quality [30]. In that case, sleep quality
was affected by frequency of post-traumatic stress symptoms, depression, restless leg syn-
drome, high diastolic blood pressure, and pain [30].
One hypothesis to explain these connections is that fatigue (reported prevalence post-kid-
ney transplantation: 40%-50% [31]) interferes with perceived sleep quality. It also limits a per-
son’s ability to carry out ordinary daily activities, with a bidirectional impact on sleep [32].
Daytime sleepiness improves [22] after kidney transplantation; however, those for whom it
persists are more prone to immunosuppression non-adherence [33]. No [22] or little improve-
ment [34] was found with objective measurements such as melatonin secretion or circadian
rhythms.
No significant change over time was found in heart and lung transplant recipients. Their
slope showed fluctuation that could represent the health instability in these transplant recipi-
ents. In a qualitative study the recipients’ uncertainty reflected their complex medication regi-
mens, unpredictable future health/prognosis, and complex role and identity challenges [35].
Heart and lung transplant recipients’ medication regimen may also be more complex than
those of liver and kidney recipients [36, 37].
Characteristics of transplant recipients with persistent poor SQ over time
Transplant recipients with persistent poor SQ (10% of the sample) need to consult with a sleep
medicine expert. Occasionally, not getting enough sleep is completely normal; however, over
months and years, poor SQ results in a suffering trajectory. E.g., we found that transplant
Table 4. Poor SQ over time (in years) with interactions across different organ transplant groups.
Contrast Odds ratio (95% confidence interval) Chi2 value p-value
Heart 0.84 (0.69;1.04) 2.5 0.1139
Kidney 0.91 (0.84;0.97) 7.79 0.0052
Liver 0.80 (0.69;0.93) 8.45 0.0037
Lung 1.03 (0.86;1.24) 0.13 0.7164
Explanation: Logistic regression model predicting poor SQ (N = 1173), controlling for gender and
depressive symptomatology and including an interaction between organ groups and continuous time.
Because of nonlinearities between pre- and post-transplant time-points, only post-transplant data were
included. Odds rations represent regression slopes over time for the different organs.
https://doi.org/10.1371/journal.pone.0185036.t004
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recipients with persistent poor SQ score significantly higher on the depressive symptomatol-
ogy scale. This association mainly corroborates previous findings [38, 39] in transplant recipi-
ents. Among patients with lower educational levels and more depressive symptomatology, the
predisposition for poor SQ has previously been confirmed by Patel et. al. [40] and in a review
by Tsuno et.al. [41].
Transplant recipients whose poor SQ persisted over extended periods had a significantly
lower mean global quality of life compared to those with consistently good or variable sleep qual-
ity. A study including patients suffering from chronic illnesses such as coronary artery disease
showed that both sleep quality and sleep quantity impact these patients´ quality of life [42]. This
is congruent with a recent review´s finding that pronounced persistent poor sleep is a major risk
for psychiatric, cardiovascular, metabolic or hormonal co-morbidity and mortality [43].
We found no increased mortality risk among transplant recipients whose poor SQ persisted
over time. Poor SQ, depression and poor global quality of life commonly co-occur in trans-
plant recipients in ways that suggest bi-directional influence. Evidence that poor SQ is part of
a cluster of symptoms has been found in cancer patients [44]. However, further studies are
needed as a recent study (N = 152 renal transplant recipients) reported an amelioration of
renal function post-transplantation that improved several aspects of quality of life, but with no
beneficial effect on self-reported sleep [30]. Finally, as the high prevalence of poor SQ is an
increasing public health issue [45], its associations with poorer outcomes indicate a need for
regular assessment.
Clinical relevance and possible interventions
Of the sleep assessment methods currently available, self-reporting is the most accessible, least
expensive and simplest to integrate into daily clinical practice [1, 3]. Our analysis showed no
Table 5. Sample characteristics at pre-transplant overall and per sleep quality pattern.
Overall Persistent poor
SQ
Consistently good or variable
SQ
p
N (%) 1136 (100) 107 (10.4) 1029 (90.6)
Age Mean (std) in years (Age range 18–79
years)
52.10
±13.23
49.98 ±10.86 52.32 ±13.44 0.02
Gender Male–N (%) 748 (65.85) 60 (56.07) 688 (66.86) 0.0664
Living situation Married/living together–N (%) 750 (66.61) 63 (60.00) 687 (67.29) 0.0449
Highest completed educational
level
No completed high school N (%) 779 (68.88) 86 (80.37) 693 (67.68) 0.0312
High school graduate N (%) 72 (6.37) 5 (4.67) 67 (6.54)
Some college N (%) 173 (15.30) 7 (6.54) 166 (16.21)
College graduate N (%) 107 (9.46) 9 (8.41) 98 (9.58)
Time between inclusion in STCS
and Tx
Mean (std) in years 7.89 ±9.49 7.08 ±8.53 7.98 ±9.58 0.62
Depressive symptomatology Median (25th; 75th Percentile) 4 (2; 7) 7 (4; 11) 4 (2; 7) <
.0001
Nr. Comorbidities Median (25th; 75th Percentile) 2 (1; 2) 2 (1; 2) 2 (1; 2) 0.9900
Global quality of life pre-Tx Mean (std) range 0–100 55.89
±22.56
42.19±21.01 57.31±22.25 <
.0001
Global quality of life post-Tx Mean (std) range 0–100 74.34
±17.67
59.69±21.51 75.63 ±16.68 0.0001
Survival Probability at max 6 years post-Tx 0.83 0.79 0.83 0.6154
Explanation: Patients were divided into two groups based on their longitudinal sleeping patterns: those who had persistent poor SQ and all others.
Differences were explored between these 2 groups.
https://doi.org/10.1371/journal.pone.0185036.t005
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association between poor SQ and lower survival; however, the dialysis Outcome and Practice
Patterns Study associated poor SQ with higher mortality [1]. Therefore, it is worth integrating
this simple question into standard follow-up care while monitoring other parameters.
If during the follow-up visit a score>6 on the single-item self-report of SQ is given, a more
in-depth questionnaire or a sleep assessment-asking among other things, about sleep aids
should follow. Transplant recipients are educated not to take over-the-counter medicines or
herbal supplements without first discussing them with the transplant clinician [46]. In the gen-
eral population, use of over-the-counter sleep aids (e.g., herbal pills, melatonin or antihysta-
mines) is common [47]. However herbal formulations with an anxiolytic and sedative effect
might precipitate liver failure [48]. Even in healthy people, sleep aids are always potentially
toxic to the kidneys and liver [49], with common adverse effects including daytime somno-
lence or decreased alertness [50]. Additional risks have to be acknowledged for all transplant
patients. To deal with the problem of persistent poor sleep quality, though, it is crucial to know
which factors or combinations of factors influence patients’ perceptions of their SQ. To under-
stand these factors and move forward, system-level improvement is needed in transplant recip-
ient follow-up care.
Strength and limitation
A limitation of the Swiss Transplant Cohort Study, is that, in the interests of their instrument
´s overall feasibility, its designers could include only a very short and quick scale on SQ. Com-
pared to a well-established tool such as the Pittsburgh Sleep Quality Index, our single-item
solution is a weak measurement of sleep quality. As a counterpoint, the Swiss Transplant
Cohort Study includes a large sample of solid organ transplant recipients reporting sleep qual-
ity issues over time.
One further weakness is that the Swiss Transplant Cohort Study psychosocial questionnaire
does not permit investigation of specific sleep disorders such as restless leg syndrome, periodic
limb movement, or sleep apnea. However this single-item scale´s validity has been confirmed
in kidney studies, suggesting further uses in the clinical context of organ transplantation [1–3].
This single-item SQ measurement could easily be incorporated in ambulatory clinic follow-up
care for transplant recipients.
Conclusion
Sleep quality improved following transplantation; but poor sleep quality was prevalent in kid-
ney, heart, liver and lung transplanted patients. Therefore, SQ should be assessed routinely in
solid organ transplant recipients.
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